FrancophonIA/ELRC3.0 huggingface dataset:
English: According to the TLOVR non-virologic failure censored algorithm 24 (30.0%) patients experienced virological failure, of which 17 (21.3%) patients were rebounders and 7 (8.8%) patients were nonresponders.
Maltese: Skont l-algoriżmu ċċensurat ta' falliment mhux viroloġiku ta' TLOVR 24 (30.0%) pazjent esperjenzaw falliment viroloġiku, li minnhom 17 -il pazjent (21.3%) reġgħu lura għal li kienu u 7 (8.8%) pazjenti ma rrispondewx għall-kura.
English: 300 mg once daily atazanavir AUC ↔ atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11% #darunavir AUC ↔ darunavir Cmin ↔ #darunavir Cmax ↔
Maltese: 300 mg darba kuljum atazanavir AUC ↔ atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
English: Medicinal products that affect darunavir exposure (cobicistat as pharmacoenhancer)
Maltese: Prodotti mediċinali li jaffettwaw l-esponiment għal darunavir (cobicistat bħala farmakointensifikatur)
English: Darunavir Mylan contains sodium
Maltese: Darunavir Mylan fih sodium
English: Immune system disorders Uncommon immune reconstitution inflammatory syndrome, (drug) hypersensitivity
Maltese: Disturbi fis-sistema immuni Mhux komuni sindrome infjammatorju ta' rikostituzzjoni immuni, sensittività eċċessiva (għall-mediċina)
English: Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to darunavir coadministered with ritonavir (600/100 mg twice daily) by baseline genotype a, and baseline darunavir FC and by use of enfuvirtide (ENF): As treated analysis of the POWER and DUET trials.
Maltese: Proporzjon (%) ta' pazjenti b'rispons (HIV-1 RNA < 50 kopja/ml fl-24 ġimgħa) għal darunavir amministrat flimkien ma' ritonavir (600 mg/100 mg darbtejn kuljum) skond il-ġenotip fil-linja bażi a, u l-FC ta' darunavir fil-linja bażi u permezz ta' l-użu ta' enfuvirtide (ENF):
English: A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the presence of low dose ritonavir.
Maltese: Studju kliniku bl-użu ta' taħlita ta' prodotti mediċinali li jiġu mmetabolizzati miċ-ċitokromi CYP2C9, CYP2C19 u CYP2D6 urew żieda fl-attività ta' CYP2C9 u CYP2C19 u impediment fl-attività ta' CYP2D6 fil-preżenza ta' darunavir/ritonavir, li tista' tkun attribwita għall-preżenza ta' doża baxxa ta' ritonavir.
English: Daily doses of 150, 450 and 1,000 mg/kg were administered to mice and doses of 50, 150 and 500 mg/kg were administered to rats.
Maltese: Dożi kuljum ta' 150, 450 u 1,000 mg/kg kienu mogħtija lillġrieden u dożi ta' 50, 150 u 500 mg/kg kienu mogħtija lill-firien.
English: copies/ml and CD4+ cell count ≥ 100 cells x 10
Maltese: CD4+ ≥ 100 ċelluli x 10
English: Based on theoretical considerations boosted darunavir may increase the exposure to glecaprevir and pibrentasvir.
Maltese: Abbażi ta' konsiderazzjonijiet teoretiċi darunavir intensifikat jista' jżid lesponiment għal glecaprevir u pibrentasvir.
English: Each tablet contains 150 milligram of darunavir.
Maltese: Kull pillola fiha 150 milligramma ta' darunavir.
English: - The other ingredients are colloidal anhydrous silica, cellulose microcrystalline, crospovidone, sodium starch glycolate, hypromellose, magnesium stearate.
Maltese: - Is-sustanzi l-oħra huma colloidal anhydrous silica, cellulose microcrystalline, crospovidone, sodium starch glycolate, hypromellose, magnesium stearate.
English: In women receiving darunavir/ritonavir 600/100 mg twice daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC12h and Cmin were 28%, 26% and 26% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC12h and Cmin values were 18%, 16% lower and 2% higher, respectively, as compared with postpartum.
Maltese: F'nisa li kienu qed jirċievu darunavir/ritonavir 600/100 mg darbtejn kuljum waqt it-tieni trimestru tattqala, il-valuri medji intraindividwali għal Cmax, AUC12-il siegħa u Cmin ta' darunavir totali kienu 28%, 26% u 26% inqas, rispettivament meta mqabbla ma' wara t-twelid; waqt it-tielet trimestru tat-tqala, ilvaluri ta' Cmax, AUC12-il siegħa u Cmin għal darunavir totali kienu 18%, 16% inqas u 2% ogħla, rispettivament, meta mqabbla ma' wara t-twelid.
English: Darunavir is approximately 95% bound to plasma protein.
Maltese: Bejn wieħed u ieħor 95% ta' darunavir huwa mwaħħal mal-proteini tal-plażma.
English: In women receiving darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 33%, 31% and 30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum.
Maltese: F'nisa li kienu qed jirċievu darunavir/ritonavir 800/100 mg darba kuljum waqt it-tieni trimestru tattqala, il-valuri medji intraindividwali għal Cmax, AUC24 siegħa u Cmin ta' darunavir totali kienu 33%, 31% u 30% inqas, rispettivament meta mqabbla ma' wara t-twelid; waqt it-tielet trimestru tat-tqala, il-valuri ta' Cmax, AUC24 siegħa u Cmin għal darunavir totali kienu 29%, 32% u 50% inqas, rispettivament, meta mqabbla ma' wara t-twelid.
English: Rare dyspnoea, cough, epistaxis, throat irritation rhinorrhoea
Maltese: Rari qtugħ ta' nifs, sogħla, epistassi, irritazzjoni filgerżuma rinorea
English: (1.6; 24.1)d d
Maltese: (-2.3; 13.0)d
English: In a study conducted in rats, the number of corpora lutea and implantations were decreased in the presence of maternal toxicity.
Maltese: Fi studju li sar fil-firien, in-numru ta' corpora lutea u implantazzjonijiet kienu mnaqqsa fil-preżenza ta' tossiċità ta' l-omm.
English: Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates of these transporters can result in increased plasma concentrations of these compounds (e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction table below).
Maltese: Ritonavir jinibixxi t-trasportaturi OATP1B1 u OATP1B3 tal-glikoproteina P, u l-għoti flimkien ma' sustrati ta' dawn it-trasportaturi jista' jwassal għal żieda fil-konċentrazzjonijiet ta' dawn is-sustanzi filplażma (eż. dabigatran etexilate, digoxin, statins u bosentan; ara t-Tabella ta' interazzjoni hawn taħt).
English: Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e.g. rifampicin, St John's wort, lopinavir).
Maltese: Prodotti mediċinali li jinduċu l-attività ta' CYP3A jkunu mistennija li jżidu t-tneħħija ta' darunavir u ritonavir bir-riżultat ta' konċentrazzjonijiet imnaqqsa ta' darunavir u ritonavir fil-plażma (eż. rifampicin, St John's wort, lopinavir).
English: darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir a TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 400
Maltese: Algoritmu ċċensurat TLOVR mhux-VF ibbażat fuq HIV-1 RNA < 50 kopja/ml, minbarra għal TITAN (HIV-1 RNA < 400 kopja/ml)
English: Darunavir/ritonavir 800/100 mg once daily + OBR
Maltese: Darunavir/ritonavir 800/100 mg darba kuljum + OBR
English: Uncommon hepatic enzyme increased hepatitis*, cytolytic hepatitis*
Maltese: Mhux komuni epatite*, epatite ċitolitika*
English: Rare thrombocytopenia, neutropenia, anaemia, leucopenia increased eosinophil count
Maltese: Rari tromboċitopenija, newtropenija, anemija, lewkopenija żieda fl-għadd ta' eosinofili
English: Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitors, ATC code: J05AE10.
Maltese: Antivirali għall-użu sistemiku, inibituri tal-protease, Kodiċi ATC:
English: 600 mg darunavir/100 mg ritonavir twice daily a ritonavir oral solution: 80 mg/ml
Maltese: 600 mg darunavir/100 mg ritonavir darbtejn kuljum a soluzzjoni orali ta' ritonavir: 80 mg/ml
English: Darunavir/ritonavir (600/100 mg twice daily or 800/100 mg once daily) in combination with a background regimen was evaluated in a clinical trial of 36 pregnant women (18 in each arm) during the second and third trimesters, and postpartum.
Maltese: Darunavir/ritonavir (600/100 mg darbtejn kuljum jew 800/100 mg darba kuljum) flimkien ma' pjan terapewtiku fl-isfond ġie stmat fi prova klinika ta' 36 mara tqila (18 f'kull fergħa) waqt it-tieni u ttielet trimestri tat-tqala, u wara t-twelid.
English: Darunavir Mylan 75 mg film-coated tablets PVC/PE/PVDC-Al blister pack containing 480 tablets and 480x1 tablets.
Maltese: Darunavir Mylan 75 mg pilloli miksijin b'rita Folja tal-PVC/PE/PVDC-Al li fiha 480 pillola u 480 x1 pillola.
English: These results were confirmed in the analysis of data at 96 weeks of treatment in the TITAN trial, with 60.4% of patients in the darunavir/ritonavir arm having HIV-1 RNA < 50 copies/ml at week 96 compared to 55.2% in the lopinavir/ritonavir arm [difference: 5.2%, 95% CI (-2.8; 13.1)].
Maltese: TITAN, b'60.4% tal-pazjenti fil-fergħa ta' darunavir/ritonavir li kellhom HIV-1 RNA < 50 kopja/ml fis-96 ġimgħa meta kienu mqabbla ma' 55.2% fil-fergħa ta' lopinavir/ritonavir [differenza: 5.2%, 95% CI (-2.8; 13.1)].
English: 800 mg darunavir/100 mg ritonavir once daily a ritonavir oral solution: 80 mg/ml
Maltese: 800 mg darunavir/100 mg ritonavir darba kuljum a soluzzjoni orali ta' ritonavir: 80 mg/ml
English: Manufacturers
Maltese: PRODOTTI
English: Unchanged darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively.
Maltese: L-ammont ta' darunavir mhux mibdul kien ta' bejn wieħed u ieħor 41.2% u 7.7% tad-doża amministrata flippurgar u fl-awrina rispettivament.
English: ethinylestradiol Cmax  14% € with darunavir/cobicistat ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔ β with darunavir/ritonavir
Maltese: AUC ta' ethinylestradiol ↓ 44% β Cmin ta' ethinylestradiol ↓ 62% β Cmax ta' ethinylestradiol ↓ 32% β AUC ta' norethindrone ↓ 14% β Cmin ta' norethindrone ↓ 30% β Cmax ta' norethindrone ↔ β β b'darunavir/ritonavir
English: HIV-1 RNA < 50 copies/ml c
Maltese: HIV-1 RNA < 50 kopji/ml c
English: HDPE bottle pack with a PP screw cap containing 30, 60, 90 tablets.
Maltese: Flixkun tal-HDPE b'tapp bil-kamini tal-PP li jkun fih 30, 60, u 90 pillola.
English: Amlodipine Diltiazem Felodipine Nicardipine Nifedipine Verapamil
Maltese: Adenomi taċċelloli follikulari tat-tirojde kienu nnutati fil-firien irġiel.
English: Lopinavir/ ritonavir 400/100 mg twice daily + OBR N=297
Maltese: lopinavir/ritonavir 400/100 mg darbtejn kuljum + OBR N=297
English: Darunavir Mylan 150 mg film-coated tablets PVC/PE/PVDC-Al blister pack containing 240 tablets and 240x1 tablets.
Maltese: Darunavir Mylan 150 mg pilloli miksijin b'rita Folja tal-PVC/PE/PVDC-Al li fiha 240 pillola u 240 x1 pillola.
English: Darunavir Mylan 75 mg film-coated tablets are available in blister packs containing 480 tablets and in plastic bottles containing 480 tablets.
Maltese: Duranavir Mylan 75 mg pilloli miksija b'rita huwa disponibbli f'pakketti bil-folji li fihom 480 pillola u fi fliexken tal-plastik li fihom 480 pillola.
English: Polyvinyl alcohol partially hydrolysed Titanium dioxide (E171) Macrogol
Maltese: Rita ta' barra tal-pillola Polyvinyl alcohol parzjalment idrolizzat Titanium dioxide (E171) Macrogol
English: Blister carton 480 film-coated tablets 480 x 1 film-coated tablets
Maltese: Kaxxa tal-kartun bil-folji 480 pillola miksija b'rita 480 x 1 pillola miksija b'rita
English: tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21% darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑ tenofovir from effect on MDR-1 transport in the renal tubules)
Maltese: tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% darunavir Cmin ↑ 24% darunavir Cmax ↑ 16% (↑ tenofovir milleffett fuq it-trasport b'MDR-1 fit-tubi żżgħar tal-kilwa)
English: PI
Maltese: Piż
English: Posology
Maltese: Listi
English: PVC/PE/PVDC-Al blister pack containing 30, 60 and 120 tablets and 120x1 tablets.
Maltese: Folja tal-PVC/PE/PVDC-Al f'forma kiesħa li fiha 30, 60, u 120 pillola u 120 x1 pillola.
English: In most cases, darunavir can be combined with anti-HIV medicines belonging to another class [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)].
Maltese: F'ħafna mill-każi darunavir jista' jittieħed flimkien ma' mediċini li jagħmlu parti minn klassi oħra [eż. NRTI's (impedituri tan-nucleoside reverse transcriptase), NNRTI's (impedituri tan-non-nucleoside reverse transcriptase), antagonisti ta' CCR5 u FIs (impedituri ta' fużjoni)].
English: HIV-1 RNA < 50 copies/ml a
Maltese: HIV-1 RNA < 50 kopja/ml a
English: TITAN is a randomised, controlled, open-label Phase III trial comparing darunavir co-administered with ritonavir (600/100 mg twice daily) versus lopinavir/ritonavir (400/100 mg twice daily) in ARTexperienced, lopinavir naïve HIV-1 infected adult patients.
Maltese: TITAN hija prova tal-Fażi III randomised, ikkontrollata, open-label, li tqabbel darunavir mogħti flimkien ma' ritonavir (600/100 mg darbtejn kuljum) versus lopinavir/ritonavir (400/100 mg darbtejn kuljum) f'pazjenti adulti infettati bl-HIV-1 li ġieli ħadu ART qabel iżda qatt ma ħadu lopinavir.
English: Each tablet contains 300 milligram of darunavir.
Maltese: Kull pillola fiha 300 milligramma ta' darunavir.
English: 600 milligram darunavir + 100 milligram ritonavir twice a day
Maltese: 600 milligramma darunavir + 100 milligramma ritonavir darbtejn kuljum
English: Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% #darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
Maltese: Nevirapine 200 mg darbtejn kuljum nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% #darunavir: il-konċentrazzjonijiet kienu konsistenti ma' dejta storika.
English: Rare diarrhoea vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia stomatitis, haematemesis, cheilitis, dry lip, coated tongue
Maltese: Rari pankreatite, gastrite, mard ta' rifluss gastroesofagali, stomatite bl-afte, taqligħ, ħalq xott, nefħa fl-addome, skonfort fl-addome, stitikezza, żieda fil-lipase, tifwieq, disastesija orali,
English: During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%, 63%, and 83% lower, respectively, as compared with postpartum.
Maltese: Matul it-tieni trimestru tat-tqala, is-Cmax, l-AUC24h, u s-Cmin ta' cobicistat kienu 50%, 63%, u 83% aktar baxxi, rispettivament, meta mqabbla ma' wara t-twelid.
English: Musculoskeletal and connective tissue disorders Common
Maltese: Disturbi muskoluskeletriċi u tat-tessuti konnettivi Komuni
English: 450 mg darunavir/60 mg ritonavir twice daily
Maltese: 450 mg darunavir/60 mg ritonavir darbtejn kuljum
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N=18
Maltese: Diġà ħadu kura qabel darunavir/cobicistat 800/150 mg darba kuljum+ OBR N=18
English: Other c
Maltese: Tip C
English: EU/1/16/1140/006 EU/1/16/1140/007 EU/1/16/1140/008 EU/1/16/1140/009 EU/1/16/1140/010 EU/1/16/1140/011
Maltese: EU/1/16/1140/006 EU/1/16/1140/007 EU/1/16/1140/008 EU/1/16/1140/009 EU/1/16/1140/010
English: During the third trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin, were 27%, 49%, and 83% lower, respectively, as compared with postpartum.
Maltese: Matul it-tielet trimestru tat-tqala, is-Cmax, l-AUC24h, u s-Cmin ta' cobicistat kienu 27%, 49%, u 83% aktar baxxi, rispettivament, meta mqabbla ma' wara t-twelid.
English: Blister carton 240 film-coated tablets 240 x 1 film-coated tablets
Maltese: Kartuna bil-folji 240 pillola miksija b'rita 240 x 1 pillola miksija b'rita
English: Each tablet contains 400 milligrams of darunavir.
Maltese: Kull pillola fiha 400 milligramma ta' darunavir.
English: For additional clinical study results in ART-experienced adults and paediatric patients, refer to the Summary of Product Characteristics for darunavir 75 mg, 150 mg, 300 mg or 600 mg tablets.
Maltese: Għal riżultati addizzjonali ta' studji kliniċi f'pazjenti adulti u pedjatriċi li digà ħadu ART, ara sSommarju ta' Karatterisiċi tal-Prodott għal pilloli ta' darunavir 75 mg, 150 mg, 300 mg jew 600 mg.
English: Darunavir 400 mg or 800 mg must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products (see section 5.2).
Maltese: Darunavir 400 mg jew 800 mg għandu dejjem jingħata mill-ħalq flimkien ma' cobicistat jew doża baxxa ta' ritonavir bħala intensifikatur farmakokinetiku u flimkien ma' prodotti mediċinali antiretrovirali oħra (ara sezzjoni 5.2).
English: Ethinylestradiol Norethindrone 35 μg/1 mg once daily drospirenone AUC ↑ 58% drospirenone Cmin ND€
Maltese: Ethinylestradiol Norethindrone 35 g/1 mg darba kuljum
English: Cold form PVC/Al/OPA-Al blister pack containing 240 tablets and 240x1 tablets.
Maltese: Folja tal-PVC/PE/PVDC-Al f'forma kiesħa li fiha 240 pillola u 240 x1 pillola.
English: Psychiatric disorders Common abnormal dreams
Maltese: Disturbi psikjatriċi Komuni insomnja
English: The steady-state pharmacokinetic parameters of darunavir were comparable when boosted with cobicistat versus ritonavir.
Maltese: Il-parametri farmakokinetiċi ta' darunavir flistat fiss kienu kumparabbli meta kien intensifikat b'cobicistat versus ritonavir.
English: Rare acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria decreased creatinine renal clearance
Maltese: Rari insuffiċjenza renali akuta, insuffiċjenza renali, nefrolitiażi, żieda fil-kreatinina fid-demm, proteinurja, bilirubinurja, disurja, nokturja, pollakijurja tnaqqis fit-tneħħija renali tal-kreatinina
English: Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'.
Maltese: Darunavir Mylan 75 mg, 150 mg, 300 mg, u 600 mg pilloli miksijin b'rita fihom inqas minn 1 mmol sodium (23 mg) f'kull doża, u għalhekk huma prattikament ħielsa mis-sodium.
English: An increase of systemic exposure to darunavir was observed when darunavir coadministered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
Maltese: Żieda fl-esponiment sistemiku għal darunavir kienet osservata meta darunavir mogħti flimkien ma' 100 mg ritonavir ingħata flimkien ma' rifabutin (150 mg ġurnata iva u oħra le).
English: Darunavir/ ritonavir 600/100 mg twice daily n=131
Maltese: Darunavir/ ritonavir 600/100 mg darbtejn kuljum n=131
English: drospirenone Cmax ↑ 15% ethinylestradiol AUC  30% ethinylestradiol Cmin ND€
Maltese: Ethinylestradiol Norethindrone 35 g/1 darba kuljum drospirenone AUC ↑ 58%€ drospirenone Cmin ND drospirenone Cmax ↑ 15%€ ethinylestradiol AUC  30% ethinylestradiol Cmin ND€ ethinylestradiol Cmax  14%€ b'darunavir/cobicistat
English: Concomitant use of boosted darunavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
Maltese: L-użu ta' darunavir intensifikat u elbasvir/grazoprevir huwa kontraindikat (ara sezzjoni 4.3).
English: In an interaction study #, a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with darunavir and low dose ritonavir.
Maltese: Fi studju ta' interazzjoni#, esponiment sistemiku kumparabbli għal sildenafil kien osservat bit-teħid ta' doża unika ta' 100 mg sildenafil waħdu u teħid ta' doża unika ta' 25 mg sildenafil mogħti ma' darunavir flimkien ma' doża baxxa ta' ritonavir.
English: HIV-1 RNA < 50 copies/mla CD4+ percent change from baseline b
Maltese: HIV-1 RNA < 50 kopji/mla CD4+ bidla perċentwali mil-linja bażi ta' riferiment b
English: Tell your doctor if you take: - Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaide, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
Maltese: Għid lit-tabib tiegħek jekk inti tieħu: - Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (għall-mard tal-qalb) minħabba li l-effett terapewtiku jew l-effetti sekondarji ta' dawn il-mediċini jistgħu jiżdiedu.
English: - Itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole (to treat fungal infections).
Maltese: - Digoxin (biex tikkura ċertu mard tal-qalb) - Clarithromycin (antibijotiku) - Itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole (biex tikkura infezzjonijiet fungali).
English: Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, fluticasone, and bosentan) is not recommended (see interaction table below).
Maltese: L-għoti ta' darunavir/cobicistat flimkien ma' indutturi ħfief jew moderati ta' CYP3A (eż. efavirenz, etravirine, nevirapine, boceprevir, fluticasone, u bosentan) mhuwiex irrakkomandat (ara t-tabella ta' interazzjoni taħt).
English: Medicinal products that affect darunavir exposure (ritonavir as pharmacoenhancer)
Maltese: Prodotti mediċinali li jaffettwaw l-esponiment għal darunavir (ritonavir bħala farmokointensifikatur)
English: ANTIBIOTIC Clarithromycin 500 mg twice daily clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% #darunavir Cmin ↑ 1% darunavir Cmax ↓ 17% 14-OH-clarithromycin concentrations were not detectable when combined with darunavir/ritonavir.
Maltese: ANTIBIJOTIKU Clarithromycin 500 mg darbtejn kuljum clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% darunavir Cmin ↑ 1% darunavir Cmax ↓ 17% Konċentrazzjonijiet ta' 14-OH-clarithromycin ma kinux b'tali mod li setgħu jiġu identifikati meta ngħata flimkien ma' darunavir/ritonavir. (↑ clarithromycin minn impediment ta' CYP3A u x'aktarx minn impediment ta' P-gp)
English: #darunavir AUC ↔ darunavir Cmin ↔
Maltese: Kif għandek tieħu Darunavir Mylan
English: Cold form PVC/Al/OPA-Al blister pack containing 480 tablets and 480x1 tablets.
Maltese: Folja tal-PVC/PE/PVDC-Al f'forma kiesħa li fiha 480 pillola u 480 x1 pillola.
English: St John's wort is expected to decrease the plasma concentrations of darunavir and ritonavir.
Maltese: St John's wort huwa mistenni li jnaqqas il-konċentrazzjonijiet ta' darunavir u ritonavir fil-plażma.
English: Rare conjunctival hyperaemia, dry eye visual disturbance
Maltese: Rari iperimija konġuntivali, għajn xotta disturb tal-vista
English: 375 mg darunavir/50 mg ritonavir twice daily
Maltese: 375 mg darunavir/50 mg ritonavir darbtejn kuljum
English: In a multiple dose study with darunavir co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, n=8) and moderate (ChildPugh Class B, n=8) hepatic impairment were comparable with those in healthy subjects.
Maltese: Fi studju b'dożi multipli ta' darunavir amministrat flimkien ma' ritonavir (600/100 mg) darbtejn kuljum, intwera bil-provi li lkonċentrazzjonijiet totali ta' darunavir fil-plażma f'individwi b'indeboliment epatiku ħafif (Child-Pugh Klassi A, n=8) u moderat (Child-Pugh Klass B, n=8) kienu kumparabbli ma dawk ta' individwi b'saħħithom.